NRx Pharmaceuticals prices 5,714,286-share follow-on at $3.5 per share

NRx Pharmaceuticals

NRx Pharmaceuticals

NRXP

0.00
  • NRx Pharmaceuticals priced an underwritten follow-on offering of 5,714,286 common shares at USD 3.5 each.
  • Gross proceeds expected at about USD 20 million; up to USD 23 million if underwriters exercise a 30-day option for 857,142 shares.
  • Closing expected June 4, 2026, subject to customary conditions.
  • Net proceeds earmarked for working capital, general corporate purposes, growth support.
  • BTIG named lead bookrunner; Lucid Capital Markets joint bookrunner.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606030818PRIMZONEFULLFEED9731258) on June 03, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.